文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

针对 SARS-CoV-2 和其他人类冠状病毒的中和抗体。

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.

机构信息

Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China.

Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.

出版信息

Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.

DOI:10.1016/j.it.2020.03.007
PMID:32249063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7129017/
Abstract

Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.

摘要

由严重急性呼吸系统综合征冠状病毒 2 型（也称为 2019 年新型冠状病毒）引起的 2019 年冠状病毒病（COVID-19）正在威胁着全球公共卫生、社会稳定和经济发展。为应对这一挑战，本文讨论了预防和治疗 SARS-CoV-2 及其他人类冠状病毒感染的中和抗体（nAbs）的研究和开发进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae0c/7129017/15d8ae2a8ebd/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae0c/7129017/15d8ae2a8ebd/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae0c/7129017/15d8ae2a8ebd/gr1_lrg.jpg

相似文献

[1]
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.

Trends Immunol. 2020-4-2

[2]
[Not Available].

Rev Med Suisse. 2020-6-10

[3]
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.

Nature. 2020-7-22

[4]
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.

Science. 2020-6-15

[5]
Monoclonal Antibodies for Prevention and Treatment of COVID-19.

JAMA. 2020-7-14

[6]
Coronaviruses pandemics: Can neutralizing antibodies help?

Life Sci. 2020-5-22

[7]
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.

Int J Biol Sci. 2020-3-15

[8]
COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.

Front Immunol. 2020-5-29

[9]
Rapid COVID-19 vaccine development.

Science. 2020-5-29

[10]
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.

Nature. 2020-7-29

引用本文的文献

[1]
Mathematical modelling of the heterogeneity of disease progression and treatment outcomes in patients with COVID-19.

Front Microbiol. 2025-7-28

[2]
A plant secretory sequence enhances immunogenicity of electroporated COVID-19 DNA vaccines.

Front Med Technol. 2025-7-14

[3]
Construction and Evaluation of a HCoV-OC43 S2 Subunit Vaccine Fused with Nasal Immuno-Inducible Sequence Against Coronavirus Infection.

Curr Issues Mol Biol. 2025-5-13

[4]
Molecular basis of host recognition of human coronavirus 229E.

Nat Commun. 2025-2-27

[5]
A Live-Cell Imaging-Based Fluorescent SARS-CoV-2 Neutralization Assay by Antibody-Mediated Blockage of Receptor Binding Domain-ACE2 Interaction.

BioTech (Basel). 2025-2-14

[6]
A 10 Year Long-Lived Cellular and Humoral MERS-CoV Immunity Cross-Recognizing the Wild-Type and Variants of SARS-CoV-2: A Potential One-Way MERS-CoV Cross-Protection Toward a Pan-Coronavirus Vaccine.

J Med Virol. 2025-1

[7]
Adverse events associated with SARS-CoV-2 neutralizing monoclonal antibodies using the FDA adverse event reporting system database.

Toxicol Res. 2024-7-30

[8]
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.

Int J Mol Sci. 2024-7-26

[9]
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.

Vaccines (Basel). 2024-6-18

[10]
Effect of the COVID-19 Pandemic on Respiratory Diseases and Their Economic Impacts.

Pathogens. 2024-6-8

本文引用的文献

[1]
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Cell Mol Immunol. 2020-3-19

[2]
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Cell. 2020-3-5

[3]
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.

JAMA. 2020-4-21

[4]
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.

Nat Microbiol. 2020-3-2

[5]
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.

Emerg Microbes Infect. 2020-2-17

[6]
A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Nature. 2020-2-3

[7]
An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.

Emerg Microbes Infect. 2020-1-31

[8]
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Lancet. 2020-1-24

[9]
Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain.

Viruses. 2019-1-14

[10]
MERS-CoV spike protein: a key target for antivirals.

Expert Opin Ther Targets. 2017-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索